Department of Obstetrics & Gynecology, University Hospitals KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Development and Regeneration, Unit Urogenital, Abdominal and Plastic Surgery, KU Leuven, Leuven, Belgium.
Int Urogynecol J. 2023 Nov;34(11):2799-2807. doi: 10.1007/s00192-023-05631-0. Epub 2023 Aug 26.
In the case of recurrent apical prolapse following laparoscopic sacrocolpopexy (LSCP), one may consider a "redo" procedure. We hypothesized that redo LSCP may carry an increased complication risk and less favorable outcomes when compared with primary procedures.
This is a single-center, matched case-control (1:4) study, comparing all 39 women who had a redo LSCP and 156 women who had a primary LSCP for symptomatic apical prolapse between 2002 and 2020 with a minimum follow-up of 12 months. Matching was based on proximity to the operation date. The primary outcome was the occurrence of intraoperative and early postoperative complications within 3 months. Secondary outcomes included subjective (Patient Global Impression of Change [PGIC] ≥4) and objective (Pelvic Organ Prolapse Quantification [POP-Q] stage <2) success rates, surgical variables, graft-related complications and reinterventions.
There was no difference in the rate of intraoperative and early postoperative complications (redo: 21.1% vs control: 29.8%, OR: 0.63, 95% CI 0.27-1.48). The conversion rate was higher in redo patients (redo: 10.3% vs control: 0.6, OR: 17.71, 95% CI 1.92-163.39). Early postoperative complications were comparable: they were mainly infectious and managed by antibiotics. At a comparable follow-up (redo: 81 months (IQR: 54) vs control: 71.5 months (IQR: 42); p=0.37), there were no differences in graft-related complications (redo: 17.9% vs control: 9.6%, p=0.14) and reinterventions for complications (redo: 12.8% vs control: 5.1%, p=0.14) or prolapse (redo: 15.4% vs control: 8.3%, p=0.18). Subjective (redo: 88.5% vs control: 80.2%, p=0.41) and objective (redo: 31.8% vs control: 24.7%, p=0.50) success rates were also comparable.
In our experience, redo LSCP is as safe and effective as a primary LSCP, but there is a higher risk of conversion.
在腹腔镜骶骨阴道固定术(LSCP)后出现复发性顶端脱垂的情况下,可能需要考虑“再次手术”。我们假设与初次手术相比,再次 LSCP 可能会增加并发症风险和降低结局满意度。
这是一项单中心、配对病例对照(1:4)研究,比较了 2002 年至 2020 年期间因有症状的顶端脱垂而接受再次 LSCP 的 39 名女性和接受初次 LSCP 的 156 名女性,所有患者的随访时间均至少为 12 个月。配对是基于手术日期的接近程度。主要结局是 3 个月内的术中及早期术后并发症。次要结局包括主观(患者整体印象变化[PGIC]≥4)和客观(盆腔器官脱垂量化[POP-Q]分期<2)成功率、手术变量、移植物相关并发症和再次干预。
术中及早期术后并发症的发生率无差异(再次手术:21.1%;对照组:29.8%;OR:0.63;95%CI:0.27-1.48)。再次手术组的转化率更高(再次手术:10.3%;对照组:0.6%;OR:17.71;95%CI:1.92-163.39)。早期术后并发症相似,主要为感染性并发症,采用抗生素治疗。在相似的随访时间(再次手术:81 个月(IQR:54);对照组:71.5 个月(IQR:42);p=0.37),移植物相关并发症(再次手术:17.9%;对照组:9.6%;p=0.14)和并发症再次干预(再次手术:12.8%;对照组:5.1%;p=0.14)或脱垂(再次手术:15.4%;对照组:8.3%;p=0.18)无差异。主观(再次手术:88.5%;对照组:80.2%;p=0.41)和客观(再次手术:31.8%;对照组:24.7%;p=0.50)成功率也相似。
根据我们的经验,再次 LSCP 与初次 LSCP 一样安全有效,但转化率更高。